Sell...sell.....sell.....droping below 3.00........faster sell.....

why price dropping now.....should buy ?

Bintai Kinden Corporation Berhad (www.bintai.com.my) is an investment holding company headquartered in Malaysia with operations throughout South-East Asia, China, and the Arabian Gulf Region

Upfront licensing fee of $2.5 million

100% funding for development, manufacturing and commercial registration of Ii-Key- SARS-CoV-2 prophylactic vaccine against COVID-19 in Malaysia

Milestone payments totaling $17.5 million upon approval by Malaysian Ministry of Health

Contracted royalty of $3 - $4.50 per dose of vaccine

Potential $150 million in GNBT revenues for vaccine sales in Malaysia

Potential to expand the partnership and development agreement in Australia, New Zealand, and the global HALAL markets

Do not underestimate IJN team as they have done homework before signoff the MOU

The first split for GNBT took place on December 03, 2018. This was a 21 for 1 split, meaning for each share of GNBT owned pre-split, the shareholder now owned 21 shares. For example, a 1000 share position pre-split, became a 21000 share position following the split. GNBT's second split took place on October 31, 2019.

XINKEXIAN (BEIJING) BIOTECHNOLOGY
- Partnerships for Global Vaccine Development - Meningitis Vaccine Project (MVP) for Sub Saharan Africa
- Partnerships for Global Vaccine Development Rotavirus Vaccine

XINKEXIAN (BEIJING) BIOTECHNOLOGY - Real company - vaccine r&d and industrialization in china

MEMORANDUM OF UNDERSTANDING ENTERED INTO BETWEEN HWGB BIOTECH SDN BHD AND XINKEXIAN (BEIJING) BIOTECHNOLOGY CO., LTD

TP 2.00 at least soon....

https://www.theedgemarkets.com/article/ho-wah-genting-enters-second-communication-fda-covid19-vaccine